Monitor for future clinical trial updates on SAB-142, especially from the ongoing Phase 2b SAFEGUARD trial in type 1 diabetes. The capital raise extends the company's runway but increases share count significantly, watch for any changes in burn rate or development timelines.
SABS drugs
SABS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 20 $3.75entry
- T+1 · 8mo ago +4.80%α +3.70% · $3.93
- T+5 · 8mo ago +2.67%α +4.82% · $3.85
- T+20 · 7mo ago +2.93%α −6.39% · $3.86
- T+60 · 5mo ago +4.00%α −10.42% · $3.90
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
SAB Biotherapeutics (SABS) closed an underwritten public offering of 19,324,677 shares at $3.85 per share and pre-funded warrants for 2,753,246 shares at $3.8499 per warrant, raising approximately $85 million in gross proceeds. The company plans to use the funds to advance its lead candidate, SAB-142, through clinical trials for type 1 diabetes and for general corporate purposes. An additional 3,311,688-share over-allotment option remains open for 30 days.
Key Financial Metrics
Key Facts
- SAB Biotherapeutics raised $85 million in gross proceeds through a public offering.
- Offering included 19,324,677 common shares at $3.85 and pre-funded warrants for 2,753,246 shares at $3.8499.
- Proceeds will fund clinical development of SAB-142 for type 1 diabetes, manufacturing, regulatory activities, and general corporate use.
- Underwriters have a 30-day option to purchase up to 3,311,688 additional shares.
- Jefferies, UBS, Citigroup, and Barclays acted as joint book-runners.
Financial Impact
$85 million gross proceeds, with potential for additional $12.7 million if over-allotment is exercised (3,311,688 shares × $3.85)
Risk Factors
- Significant shareholder dilution from issuance of over 22 million shares and warrants.
- Clinical-stage risk: SAB-142 may fail in trials despite funding, leading to valuation decline.
- Execution risk in advancing manufacturing and regulatory plans with new capital.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3259414 |
Track record
15 reports on SABS
3 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +15.67% at T+20 after the Oct 13, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $2.96 Now $3.00 +1.35% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $2.94 Now $3.00 +2.04% settles Dec 4
- Oct 22, 202625d ago 25-NSE Neutral 2/10 Entry $2.84 Now $3.00 +5.63% settles Nov 20
- Oct 13, 20264w ago 8-K Bullish 6/10 Entry $2.68 to $3.07 Now $3.00 +11.94% ▲ +14.55% +18.16% vs SPY
- Oct 13, 20264w ago Press Release Bullish 5/10 Entry $2.68 to $3.10 Now $3.00 +11.94% ▲ +15.67% +19.34% vs SPY
- Jul 7, 202618w ago 8-K Bullish 4/10 Entry $3.90 to $3.79 Now $3.00 −23.08% ▼ −2.82% −4.15% vs SPY
- May 29, 202624w ago Press Release Neutral 3/10 Entry $3.60 to $3.90 Now $3.00 −16.67% ▲ +8.33% +10.13% vs SPY
- May 12, 202626w ago Press Release Bearish 7/10 Entry $3.62 to $3.31 Now $3.00 +17.13% ▲ +8.56% +6.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers